Mar 7 2023

Available online
An IN-VIVO Therapeutic Antibody Efficacy Evaluation


Poster abstract


For cancer drug development, a pertinent preclinical model is essential for the rapid and efficient transition from preclinical evaluation to clinical progress. Up until now, rodents are the most-often used models for preclinical evaluation. However, their use presents several drawbacks, including ethical constraints (3Rs), time-consuming and costly experiments, and the immunodeficiency of humanized models, which could slow down drug development. Since their introduction, xenografts on the chicken embryo's ChorioAllantoic Membrane (CAM) have proven extremely valuable for in vivo studies in cancerology. They are suitable for studying tumor development, angiogenesis, malignant cell dissemination, and for estimating the toxicity and the efficacy of novel therapies. Here, we demonstrate that the CAM-based in ovo model, which has an active immune system, is useful for rapidly testing and comparing therapeutic antibodies' efficacy, such as anti-PD1/PDL1 Abs, Antibody Drug Conjugates (ADCs), and others, on tumor growth and metastatic invasion. Our results clearly show the power of the chicken embryo model as an efficient in vivo model for testing a large spectrum of cancer drugs.





    GeneralQuotationPartnership / CollaborationOther

    * Fields required


    All our news

    All our webinars